July 23, 2014 6:49 PM ET

Biotechnology

Company Overview of Orchestra Therapeutics, Inc.

Company Overview

On April 12, 2012, Orchestra Therapeutics, Inc, went out of business as per its Chapter 7 liquidation filing under bankruptcy. Orchestra Therapeutics, Inc., an immuno-pharmaceutical company, focuses on the development of various products to treat autoimmune and infectious diseases. It offers NeuroVax, an immune-based therapeutic product, which is based on T-cell receptor peptide technology for the treatment of multiple sclerosis. NeuroVax is in Phase II clinical trails. The company, formerly known as The Immune Response Corporation, was founded in 1986 and changed its name to Orchestra Therapeutics, Inc. in April 2007. Orchestra Therapeutics, Inc. is headquartered in Carlsbad, California.

5931 Darwin Court

Carlsbad, CA 92008

United States

Founded in 1986

39 Employees

Phone:

760-431-7080

Fax:

760-431-8636

Key Executives for Orchestra Therapeutics, Inc.

Orchestra Therapeutics, Inc. does not have any Key Executives recorded.

Similar Private Companies By Industry

Company Name Region
ReaMetrix, Inc. United States
Cambrian Genomics Inc. United States
ChemGenes Corporation United States
Stem CentRx, Inc. United States
Targeted Technology Ventures, LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Orchestra Therapeutics, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.